570 related articles for article (PubMed ID: 28783452)
21. Posoleucel, an Allogeneic, Off-the-Shelf Multivirus-Specific T-Cell Therapy, for the Treatment of Refractory Viral Infections in the Post-HCT Setting.
Pfeiffer T; Tzannou I; Wu M; Ramos C; Sasa G; Martinez C; Lulla P; Krance RA; Scherer L; Ruderfer D; Naik S; Bocchini C; Fraser IP; Patel B; Ward D; Wang T; Heslop HE; Leen AM; Omer B
Clin Cancer Res; 2023 Jan; 29(2):324-330. PubMed ID: 36628536
[TBL] [Abstract][Full Text] [Related]
22. Outcomes following posttransplant virus-specific T-cell therapy in patients with sickle cell disease.
Kinoshita H; Mandava M; Jensen-Wachspress M; Lang H; Joy E; Tanna J; McCann CD; O'Brien S; Burnett S; Shibli A; Hoq F; Bhatia M; Hanley PJ; Dávila Saldaña B; Mahadeo KM; Bollard CM; Keller MD; Abraham A
Blood Adv; 2023 May; 7(10):2105-2116. PubMed ID: 36516084
[TBL] [Abstract][Full Text] [Related]
23. Clinical and Economic Burden of Multiple Double-Stranded DNA Viral Infections after Allogeneic Hematopoietic Cell Transplantation.
Hill JA; Moon SH; Chandak A; Zhang Z; Boeckh M; Maziarz RT
Transplant Cell Ther; 2022 Sep; 28(9):619.e1-619.e8. PubMed ID: 35764288
[TBL] [Abstract][Full Text] [Related]
24. Generation of multivirus-specific T cells by a single stimulation of peripheral blood mononuclear cells with a peptide mixture using serum-free medium.
Nishiyama-Fujita Y; Kawana-Tachikawa AI; Ono T; Tanaka Y; Kato T; Heslop HE; Morio T; Takahashi S
Cytotherapy; 2018 Sep; 20(9):1182-1190. PubMed ID: 30122653
[TBL] [Abstract][Full Text] [Related]
25. Rapid generation of clinical-grade antiviral T cells: selection of suitable T-cell donors and GMP-compliant manufacturing of antiviral T cells.
Tischer S; Priesner C; Heuft HG; Goudeva L; Mende W; Barthold M; Kloeß S; Arseniev L; Aleksandrova K; Maecker-Kolhoff B; Blasczyk R; Koehl U; Eiz-Vesper B
J Transl Med; 2014 Dec; 12():336. PubMed ID: 25510656
[TBL] [Abstract][Full Text] [Related]
26. Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT.
Neuenhahn M; Albrecht J; Odendahl M; Schlott F; Dössinger G; Schiemann M; Lakshmipathi S; Martin K; Bunjes D; Harsdorf S; Weissinger EM; Menzel H; Verbeek M; Uharek L; Kröger N; Wagner E; Kobbe G; Schroeder T; Schmitt M; Held G; Herr W; Germeroth L; Bonig H; Tonn T; Einsele H; Busch DH; Grigoleit GU
Leukemia; 2017 Oct; 31(10):2161-2171. PubMed ID: 28090089
[TBL] [Abstract][Full Text] [Related]
27. Cellular therapy for multiple pathogen infections after hematopoietic stem cell transplant.
Sutrave G; Blyth E; Gottlieb DJ
Cytotherapy; 2017 Nov; 19(11):1284-1301. PubMed ID: 28927824
[TBL] [Abstract][Full Text] [Related]
28. Viral reactivations following hematopoietic stem cell transplantation in pediatric patients - A single center 11-year analysis.
Düver F; Weißbrich B; Eyrich M; Wölfl M; Schlegel PG; Wiegering V
PLoS One; 2020; 15(2):e0228451. PubMed ID: 32017805
[TBL] [Abstract][Full Text] [Related]
29. T cells for viral infections after allogeneic hematopoietic stem cell transplant.
Bollard CM; Heslop HE
Blood; 2016 Jun; 127(26):3331-40. PubMed ID: 27207801
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapy to reconstitute immunity to DNA viruses.
Gahn B; Hunt G; Rooney CM; Heslop HE
Semin Hematol; 2002 Jan; 39(1):41-7. PubMed ID: 11799528
[TBL] [Abstract][Full Text] [Related]
31. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study.
Cruz CR; Micklethwaite KP; Savoldo B; Ramos CA; Lam S; Ku S; Diouf O; Liu E; Barrett AJ; Ito S; Shpall EJ; Krance RA; Kamble RT; Carrum G; Hosing CM; Gee AP; Mei Z; Grilley BJ; Heslop HE; Rooney CM; Brenner MK; Bollard CM; Dotti G
Blood; 2013 Oct; 122(17):2965-73. PubMed ID: 24030379
[TBL] [Abstract][Full Text] [Related]
32. The role of early natural killer cell adoptive infusion before engraftment in protecting against human herpesvirus-6B encephalitis after naïve T-cell-depleted allogeneic stem cell transplantation.
Gasior M; Ferreras C; de Paz R; Bueno D; Mozo Y; Sisinni L; Canizales JT; González B; Olivas-Mazón R; Marcos A; Romero AB; Constanzo A; Mirones I; Fernández-Arroyo A; Balas A; Vicario JL; Escudero A; Yuste VJ; Pérez-Martínez A
Transfusion; 2021 May; 61(5):1505-1517. PubMed ID: 33713461
[TBL] [Abstract][Full Text] [Related]
33. Prospective, comprehensive, and effective viral monitoring in children undergoing allogeneic hematopoietic stem cell transplantation.
Schönberger S; Meisel R; Adams O; Pufal Y; Laws HJ; Enczmann J; Dilloo D
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1428-35. PubMed ID: 20399877
[TBL] [Abstract][Full Text] [Related]
34. HA-1H T-Cell Receptor Gene Transfer to Redirect Virus-Specific T Cells for Treatment of Hematological Malignancies After Allogeneic Stem Cell Transplantation: A Phase 1 Clinical Study.
van Balen P; Jedema I; van Loenen MM; de Boer R; van Egmond HM; Hagedoorn RS; Hoogstaten C; Veld SAJ; Hageman L; van Liempt PAG; Zwaginga JJ; Meij P; Veelken H; Falkenburg JHF; Heemskerk MHM
Front Immunol; 2020; 11():1804. PubMed ID: 32973756
[TBL] [Abstract][Full Text] [Related]
35. The effects of β
Kunz HE; Agha NH; Hussain M; LaVoy EC; Smith KA; Mylabathula P; Diak D; Baker FL; O'Connor DP; Bond RA; Katsanis E; Bollard CM; Simpson RJ
Cell Stress Chaperones; 2020 Nov; 25(6):993-1012. PubMed ID: 32779001
[TBL] [Abstract][Full Text] [Related]
36. Early Experience With CliniMACS Prodigy CCS (IFN-gamma) System in Selection of Virus-specific T Cells From Third-party Donors for Pediatric Patients With Severe Viral Infections After Hematopoietic Stem Cell Transplantation.
Kállay K; Kassa C; Réti M; Karászi É; Sinkó J; Goda V; Stréhn A; Csordás K; Horváth O; Szederjesi A; Tasnády S; Hardi A; Kriván G
J Immunother; 2018 Apr; 41(3):158-163. PubMed ID: 29239916
[TBL] [Abstract][Full Text] [Related]
37. Long-Term Follow-Up after Adoptive Transfer of BK-Virus-Specific T Cells in Hematopoietic Stem Cell Transplant Recipients.
Koldehoff M; Eiz-Vesper B; Maecker-Kolhoff B; Steckel NK; Dittmer U; Horn PA; Lindemann M
Vaccines (Basel); 2023 Apr; 11(4):. PubMed ID: 37112757
[TBL] [Abstract][Full Text] [Related]
38. Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation.
Prockop S; Doubrovina E; Suser S; Heller G; Barker J; Dahi P; Perales MA; Papadopoulos E; Sauter C; Castro-Malaspina H; Boulad F; Curran KJ; Giralt S; Gyurkocza B; Hsu KC; Jakubowski A; Hanash AM; Kernan NA; Kobos R; Koehne G; Landau H; Ponce D; Spitzer B; Young JW; Behr G; Dunphy M; Haque S; Teruya-Feldstein J; Arcila M; Moung C; Hsu S; Hasan A; O'Reilly RJ
J Clin Invest; 2020 Feb; 130(2):733-747. PubMed ID: 31689242
[TBL] [Abstract][Full Text] [Related]
39. Off-the-Shelf Third-Party Virus-Specific T Cell Therapy to Treat JC Polyomavirus Infection in Hematopoietic Stem Cell Transplantation Recipients.
Rubinstein JD; Jodele S; Heyenbruch D; Wilhelm J; Thomas S; Lutzko C; Zhu X; Leemhuis T; Cancelas JA; Keller M; Bollard CM; Hanley PJ; Boghdadly ZE; Mims A; Davies SM; Grimley MS; Nelson AS
Transplant Cell Ther; 2022 Feb; 28(2):116.e1-116.e7. PubMed ID: 34785398
[TBL] [Abstract][Full Text] [Related]
40. Adoptive cellular immunotherapy for viral diseases.
Fujita Y; Rooney CM; Heslop HE
Bone Marrow Transplant; 2008 Jan; 41(2):193-8. PubMed ID: 17982497
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
